Skip to main
VNDA
VNDA logo

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals Inc. is witnessing strong growth in its product revenues, particularly with Fanapt, which achieved a 27% year-over-year revenue increase to $29.3 million in Q2 25, followed by a 31% increase in Q3 25, placing its annualized run-rate near $120 million. The recent commercial launch of Ponvory has shown promising momentum, as evidenced by record new patient prescriptions and projected gross sales ramping from $9.4 million in 2027 to $172.8 million by 2034, supported by targeted therapy utilization increases. Furthermore, enhanced promotional efforts and prescriber awareness programs have successfully driven substantial growth in new patient prescriptions and overall prescription volume, indicating a positive trajectory for Vanda Pharmaceuticals' commercial strategy.

Bears say

Vanda Pharmaceuticals Inc. has reported a decline in net product sales, with revenues of $7.1 million in the second quarter of 2025, reflecting an 18% year-over-year decrease, despite a subsequent 20% growth in the third quarter. The company's revenue base is expected to face significant pressure as market exclusivity for its key products erodes by the end of 2027, compounded by anticipated declines in oral Fanapt sales due to competition from new therapies and changes in reimbursement dynamics. Additionally, the cessation of promotional activities for Ponvory by Johnson & Johnson in 2022 highlights concerns regarding the product’s commercial viability and revenue generation potential, further reinforcing the negative outlook for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (VNDA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Vanda Pharmaceuticals (VNDA) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.